Complement components in neonatal sepsis

Area of Science:

• Immunology
• Neonatal Medicine
• Biochemistry

Background:

• Sepsis is a life-threatening condition in neonates, necessitating accurate diagnostic and prognostic markers.
• The complement system plays a crucial role in innate immunity and is implicated in sepsis pathogenesis.
• Specific complement components and their activation products may serve as valuable biomarkers.

Purpose of the Study:

• To evaluate the diagnostic and prognostic utility of complement components (C3, C1q, factor B) and C3 breakdown products (C3c, C3d) in neonatal sepsis.
• To compare complement levels in neonates with proven sepsis against healthy controls.

Main Methods:

• Quantification of complement components C3, C1q, and factor B using electroimmunodiffusion.
• Detection of C3 breakdown products (C3c, C3d) via counterimmunoelectrophoresis (CIEP).
• Study included 24 neonates with proven sepsis and matched healthy controls.

Main Results:

• Neonates with sepsis exhibited significantly lower levels of C1q and factor B compared to controls.
• No statistically significant decrease in C3 levels was observed in septic neonates.
• C3 breakdown products (C3c, C3d) were detected in 58.3% of septic neonates but absent in healthy controls.
• The extent of complement component depression did not correlate with prognostic outcomes in neonatal sepsis.

Conclusions:

• Decreased C1q and factor B levels, along with the presence of C3 breakdown products, suggest complement system activation in neonatal sepsis.
• These complement alterations may aid in the diagnosis of neonatal sepsis.
• Complement component levels lack prognostic value in this neonatal sepsis cohort.